A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 26 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
- 18 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 18 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2017.